Safety and Pharmacokinetic Characterization of Nacubactam, a Novel ?-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers.

ABSTRACT: Nacubactam is a novel ?-lactamase inhibitor with dual mechanisms of action as an inhibitor of serine ?-lactamases (classes A and C and some class D) and an inhibitor of penicillin binding protein 2 in Enterobacteriaceae The safety, tolerability, and pharmacokinetics of intravenous nacubactam were evaluated in single- and multiple-ascending-dose, placebo-controlled studies. Healthy participants received single ascending doses of nacubactam of 50 to 8,000?mg, multiple ascending doses of nacubactam of 1,000 to 4,000?mg every 8?h (q8h) for up to 7?days, or nacubactam of 2,000?mg plus meropenem of 2,000?mg q8h for 6?days after a 3-day lead-in period. Nacubactam was generally well tolerated, with the most frequently reported adverse events (AEs) being mild to moderate complications associated with intravenous access and headache. There was no apparent relationship between drug dose and the pattern, incidence, or severity of AEs. No clinically relevant dose-related trends were observed in laboratory safety test results. No serious AEs, dose-limiting AEs, or deaths were reported. After single or multiple doses, nacubactam pharmacokinetics appeared linear, and exposure increased in an approximately dose-proportional manner across the dose range investigated. Nacubactam was excreted largely unchanged into urine. Coadministration of nacubactam with meropenem did not significantly alter the pharmacokinetics of either drug. These findings support the continued clinical development of nacubactam and demonstrate the suitability of meropenem as a potential ?-lactam partner for nacubactam. (The studies described in this paper have been registered at ClinicalTrials.gov under NCT02134834 [single ascending dose study] and NCT02972255 [multiple ascending dose study].).

SUBMITTER: Mallalieu NL 

PROVIDER: S-EPMC7179653 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature